Magdalena Biosciences is focused on developing novel, natural prescription medicines derived from plants for mental health indications

Magdalena Biosciences专注于开发源自植物的新型天然处方药，用于心理健康适应症

Import of coca leaves was authorized by the Peruvian Health Authority

秘鲁卫生当局授权进口可口可乐叶

SAN FRANCISCO, CA / ACCESSWIRE / September 21, 2023 /Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar') today announced that Magdalena Biosciences, Inc. ('Magdalena'), the joint venture recently formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ('Filament' or 'Filament Health'), successfully completed an import of coca leaf to a Filament facility (Psilo Scientific) in Canada..

加利福尼亚州旧金山/ACCESSWIRE/2023年9月21日/美洲豹健康公司（纳斯达克股票代码：JAGX）（'美洲豹'）今天宣布，美洲豹最近成立的合资企业Magdalena Biosciences，Inc。（'Magdalena'）和Filament Health Corp.（OTCQB:FLHLF）（NEO:FH）（FSE:7QS）（'Filament'或'Filament Health'），成功完成了将可口可乐叶进口到灯丝设施（Psilo Scientific）在加拿大。。

Image of coca leaves. © Steven R. King

可口可乐的形象。©Steven R.King

Magdalena was founded on a mission to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD), depression, and anxiety in adults. The coca leaf imported from Peru will be used for initial research purposes to look at these and other neuropsychiatric indications..

Magdalena成立的使命是开发源自植物的新型天然处方药，用于心理健康适应症，包括成人注意力缺陷/多动障碍（ADHD），抑郁症和焦虑症。从秘鲁进口的可口可乐叶将用于初步研究目的，以查看这些和其他神经精神适应症。。

The import of coca leaves was authorized by the Peruvian Health Authority - Dirección General de Medicamentos Insumos y Drogas (DIGEMID) - and acquired from the Empresa Nacional de la Coca (ENACO), which is the only company in Peru authorized to collect, distribute, and export coca leaves and their derived products..

可口可乐叶子的进口由秘鲁卫生当局授权-DirecciónGeneral de Medicamentos Insumos y Drogas（DIGEMID）-并从秘鲁唯一授权收集的Empresa Nacional de la coca（ENACO）收购，分销和出口可口可乐叶子及其衍生产品。。

'We are grateful to the Peruvian government for their cooperation, and look forward to Magdalena initiating its pioneering research into the potential benefits of coca for ADHD, depression, and anxiety,' said Steven King, PhD, Jaguar's Chief Sustainable Supply, Ethnobotanical Research, and IP Officer and an Advisor to Magdalena, who facilitated the relationship with ENACO on behalf of Magdalena and Psilo Scientific.

“我们感谢秘鲁政府的合作，并期待Magdalena开始对可口可乐对ADHD，抑郁和焦虑的潜在益处进行开创性研究，”美洲虎首席可持续供应，民族植物学研究的Steven King博士说。，知识产权官和Magdalena的顾问，世卫组织代表Magdalena和Psilo Scientific促进了与ENACO的关系。

'In traditional medicine, coca leaves are utilized as a remedy for a wide variety of conditions, ranging from alleviating oral pain, digestive maladies, hunger, altitude sickness, as well as muscular and skeletal aches. Many commonly used neuropsychiatric medications have side effects such as personality changes or sedation.

“在传统医学中，可口可乐叶被用作各种疾病的补救措施，包括减轻口腔疼痛，消化系统疾病，饥饿，高原病，以及肌肉和骨骼疼痛。许多常用的神经精神药物都有副作用，如性格改变或镇静。

With centuries of use by Indigenous healers and traditional psychiatrists, plant-derived medicines offer potential new mechanisms of action for treating mental disorders while being potentially safer than the small molecule drugs that may have 'off target' effects.'.

随着土着治疗师和传统精神科医生几个世纪的使用，植物来源的药物为治疗精神障碍提供了潜在的新作用机制，同时可能比可能具有“脱靶”效应的小分子药物更安全。

'I am delighted that Magdalena Biosciences is proceeding with initial research on the therapeutic potential of coca leaf for ADHD, depression, and anxiety and I believe there will be benefits at multiple levels for Andean nations and for patients around the world if coca leaf products become available to help manage a diversity of medical conditions,' said Wade Davis, Ph.D.

“我很高兴Magdalena Biosciences正在对可口可乐叶对ADHD，抑郁症和焦虑症的治疗潜力进行初步研究，我相信如果可口可乐叶，安第斯国家和世界各地的患者将从多个层面获益。产品可用于帮助管理多种医疗条件，“韦德戴维斯博士说。

Dr. Davis, an adviser to Magdalena and a member of the Scientific Strategy Team for Jaguar's Entheogen Therapeutics Initiative (ETI), is an ethnobotanist, anthropologist, bestselling author, and former National Geographic Explorer-in-Residence..

戴维斯博士是马格达莱纳（Magdalena）的顾问，也是美洲豹Entheogen治疗倡议（ETI）科学战略团队的成员，他是民族植物学家，人类学家，畅销作者和前国家地理探索者。。

Once considered a childhood disorder, ADHD is now acknowledged to persist into adulthood in approximately 50-65% of individuals, and impacts an estimated 5.2% of U.S. adults aged 18-44. Treatment of ADHD remains challenging. An estimated 20-50% of adult patients either are non-responders to stimulants or cannot tolerate the adverse effects of current therapeutics.

一旦被认为是儿童期疾病，ADHD现在被认为在大约50-65%的个体中持续到成年期，并且影响估计5.2%的18-44岁的美国成年人。ADHD的治疗仍然具有挑战性。估计有20-50%的成年患者对兴奋剂无反应或不能耐受当前疗法的不良反应。

New therapeutics in development for the global ADHD market, which is projected to reach a value of US$18.69 billion by 2030 according to a report by Grand View Research, show promise but continue to have significant side effects..

根据Grand View Research的一份报告，全球ADHD市场正在开发的新疗法预计到2030年将达到186.9亿美元，显示出前景，但仍具有显着的副作用。。

Social anxiety and depression are common co-morbidities of ADHD. Social anxiety, typified as extreme fear in social settings and debilitating social withdrawal, often has an age of onset during late childhood. Common treatments include medication and psychotherapy. Unmet needs in the treatment of anxiety disorders include the need for more effective, rapidly acting, and better tolerated medications.

社交焦虑和抑郁是ADHD的常见并发症。社交焦虑症以社交环境中的极度恐惧和使社交退缩衰弱为特征，通常在儿童晚期发病。常见的治疗方法包括药物治疗和心理治疗。治疗焦虑症的未满足需求包括需要更有效，快速起效和更好耐受的药物。

Botanical drugs offer these potential advantages..

植物药提供了这些潜在的优势。。

Current medications for treatment of depression are often ineffective as well as personality altering. Unmet needs in depression include medications with greater overall effectiveness as well as improvement in the patient's ability to function day to day. Botanical drugs have the potential to meet these needs while also offering an improved safety profile..

目前用于治疗抑郁症的药物通常无效，并且性格改变。抑郁症中未满足的需求包括具有更高总体有效性的药物以及患者日常功能的改善。植物药有可能满足这些需求，同时还提供更好的安全性。。

'We are pleased to partner with Filament Health (Psilo Scientific) and Magdalena to facilitate this landmark import,' said Silveria Dongo Gonzales, Technical Director of ENACO. Richard Caballero, Director of Industrial Commercialization at ENACO, added, 'We appreciate Filament's and Magdalena's efforts to ensure that they have fully followed all of the requirements of ENACO, and that they are working through the process to obtain full compliance with the Nagoya Protocol in Peru.'.

ENACO技术总监Silveria Dongo Gonzales说：“我们很高兴与Filament Health（Psilo Scientific）和Magdalena合作，促进这一具有里程碑意义的进口。”。ENACO工业商业化总监Richard Caballero补充说：“我们感谢Filament和Magdalena为确保他们充分遵循ENACO的所有要求所做的努力，并且他们正在努力实现完全遵守名古屋议定书在秘鲁“。

Magdalena and Psilo Scientific are in the process of seeking full Nagoya Protocol compliance at this time in Peru. The Nagoya Protocol is an international agreement that ensures sharing of benefits arising from the utilization of genetic and indigenous knowledge in a fair and equitable manner.

Magdalena和Psilo Scientific目前正在秘鲁寻求完整的名古屋议定书合规性。名古屋议定书是一项国际协议，确保以公平和公平的方式分享利用遗传和土着知识所带来的利益。

ABOUT MAGDALENA BIOSCIENCES

关于MAGDALENA生物科学

Jaguar Health, Inc. and Filament Health Corp. formed Magdalena Biosciences, Inc. as a joint venture in 2023 to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD), depression and anxiety in adults. Boulder, Colorado-based One Small Planet, founded by Will Peterffy, has committed to funding of US$1,000,000.

美洲虎健康公司和灯丝健康公司于2023年成立了Magdalena Biosciences公司，作为合资企业开发新型天然处方药，用于心理健康适应症，包括注意力缺陷/多动障碍（ADHD），抑郁症和成人焦虑症。科罗拉多州博尔德市由Will Peterffy创立的一颗小行星致力于资助100万美元。

The goal of the collaboration is to extend the botanical drug development capabilities of Jaguar and Filament in order to develop pharmaceutical-grade, standardized drug candidates for mental health disorders..

该合作的目标是扩展美洲虎和长丝的植物药物开发能力，以开发药物级，精神健康障碍的标准化候选药物。。

About the Jaguar Health Family of Companies

关于美洲虎健康家族的公司

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.

美洲虎健康公司（美洲虎）是一家商业阶段制药公司，专注于为患有胃肠道不适的人和动物开发可持续衍生自雨林地区植物的新型专有处方药，特别是与肠道过度活动有关，其中包括慢性衰弱性腹泻，紧迫性和肠失禁。

Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy.

美洲虎家族公司Napo Pharmaceuticals专注于开发和商业化人体处方药，以便在多种复杂疾病状态下对被忽视的胃肠道症状进行必要的支持性护理和管理。Napo Pharmaceuticals的crofelemer候选药物是OnTarget研究的主题，OnTarget研究是一项正在进行的关键性3期临床试验，用于预防性治疗靶向治疗癌症成人化疗引起的过度活动性肠道（CIOB）。

Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp.

美洲虎家族公司Napo Therapeutics是一家意大利公司美洲虎，于2021年在意大利米兰成立，专注于扩大欧洲的crofelemer接入范围，特别针对孤儿和/或罕见疾病。美洲虎动物健康是美洲虎的商标。Magdalena Biosciences，由美洲虎和灯丝健康公司组建的合资企业。

that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications..

来自美洲虎的Entheogen Therapeutics Initiative（ETI）的是专注于开发用于心理健康适应症的植物的新型处方药。。

For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com. For more information about Magdalena Biosciences, visit magdalenabiosciences.com..

有关美洲虎健康的更多信息，请访问https://jaguar.health.有关Napo制药的更多信息，请访问www.napopharma.com。有关Napo治疗的更多信息，请访问napotherapeutics.com。有关Magdalena Biosciences的更多信息，请访问magdalenabiosciences.com。。

Visit Jagaur on LinkedIn: https://www.linkedin.com/company/jaguar-health/

Visit Jagaur on LinkedIn: https://www.linkedin.com/company/jaguar-health/

Visit Jagaur on X: https://twitter.com/Jaguar_Health

访问Jagaur on X:https://twitter.com/Jaguar_Health

Visit Jagaur on Instagram: https://www.instagram.com/jaguarhealthcommunity/

Visit Jagaur on Instagram: https://www.instagram.com/jaguarhealthcommunity/

Forward-Looking Statements

前瞻性声明

Certain statements in this press release constitute 'forward-looking statements.' In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions.

本新闻稿中的某些陈述构成“前瞻性陈述”在某些情况下，您可以通过“可能”，“将会”，“应该”，“期望”，“计划”，“目标”，“预期”，“可能”，“打算”，“目标”，“项目”，“考虑”，“相信”，“估计”，“预测”，“潜在”或“继续”或这些术语或其他类似表达式的否定。

The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control.

本版本中的前瞻性陈述仅是预测。美洲华的这些前瞻性陈述主要基于其目前对未来事件的期望和预测。这些前瞻性陈述仅在本版本发布之日起发言，并受到若干风险，不确定性和假设的约束，其中一些风险，不确定性和假设无法预测或量化，其中一些风险，不确定性和假设超出美洲华的控制范围。

Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise..

除适用法律要求外，无论是由于任何新信息，未来事件，更改情况或其他原因，美洲华均不计划公开更新或修改此处包含的任何前瞻性声明。。

Contact Info:

联系信息：

hello@jaguar.health

hello@jaguar.health

Jaguar-JAGX

捷豹JAGX

SOURCE: Jaguar Health, Inc.

来源：美洲虎健康有限公司。

View source version on accesswire.com:

在AccessWire.com上查看源版本：

https://www.accesswire.com/786068/jaguar-health-announces-import-of-coca-leaf-from-peru-by-joint-venture-magdalena-biosciences-for-research-in-treating-adhd

https://www.accesswire.com/786068/jaguar-health-announces-import-of-coca-leaf-from-peru-by-joint-venture-magdalena-biosciences-for-research-in-treating-adhd